71
Participants
Start Date
May 31, 2016
Primary Completion Date
May 7, 2020
Study Completion Date
May 7, 2020
CA-170
"Dose escalation stage (Phase 1a) accelerated titration and standard 3+3 dose escalation in patients with advanced solid tumor or lymphoma.~Dose expansion stage (Phase 1b) in patients with tumors that are shown to be responsive to anti-PD-1 or anti-PD-L1 checkpoint inhibitors and/or in tumor types known to express PD-L1 or VISTA, including but not limited to: mesothelioma, melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer."
Yonsei University Health System - Severance Hospital, Seoul
Asan Medical Center, Seoul
Icahn School of Medicine at Mt. Sinai, New York
Memorial Sloan Kettering Cancer Center, New York
University of Pittsburgh Medical Center, Pittsburgh
Hospital Universitario 12 de Octubre, Madrid
Carolina BioOncology Institute, Huntersville
Sarah Cannon Research Institute, Sarasota
Sarah Cannon Research Institute, Nashville
Karmanos Cancer Institute, Detroit
Northwestern University, Chicago
University of Texas MD Anderson Cancer Center, Houston
Sarah Cannon Research Institute at HealthONE, Denver
University of California San Francisco, San Francisco
Seoul National University Hospital, Seoul
Samsung Medical Center, Seoul
Hospital Clinic i Provincial, Barcelona
Catalan Institute of Oncology, Barcelona
Cambridge University Hospitals NHS Foundation Trust, Cambridge
Guy's and St Thomas' NHS Foundation Trust, London
Curis, Inc.
INDUSTRY